Connect with us

World News

US authorizes AstraZeneca Evushield drug to treat COVID in some cases

Published

on


US health officials today authorized the use of Evushield.

Washington, United States of America:

US health officials on Wednesday authorized the use of synthetic antibodies developed by AstraZeneca to prevent COVID-19 infection in people who react badly to vaccines.

This was the first time the Food and Drug Administration had given emergency authorization for such a purely preventive treatment.

The FDA warned that the Evusheld drug “is not a substitute for vaccination in individuals for whom COVID-19 vaccination has been recommended” and may only be authorized for those who have a weakened immune system or who have had medical reasons. Can not be vaccinated, such a strong allergic reaction.

In those cases, the drug can be given to people 12 years of age and older.

Evushield combines two types of synthetic antibodies (tixesvimab and silgavimab), and is given as two intramuscular injections, one directly after the other. These antibodies help the immune system fight the virus by targeting its spike protein, which allows it to enter cells and infect them.

The FDA said the treatment “may be effective for pre-exposure prevention for up to six months.”

It cannot be administered to someone who is already infected with the virus, the FDA said, although AstraZeneca is testing it for such treatment.

Side effects may include allergic reaction, bleeding from the injection site, headache and fatigue.

The FDA authorization was based on a clinical trial conducted on people over the age of 59, or with a chronic disease, or at high risk of infection.

The drug was given to 3,500 people while 1,700 people got a placebo. The trial showed that the treatment reduced the risk of developing COVID-19 by 77 percent.

Two cocktails of antibodies, made by Regeneron and Eli Lilly, are currently authorized for the prevention of infection in the United States, but only in people who have been exposed to the virus shortly before, or who are at high risk of exposure. such as employees of retirement homes or prisons.

In addition to being immunized or uninfected, these people should also be at high risk of developing a severe case of the disease.

,